ProMIS Neurosciences (PMN) director boosts stake with 3,050 shares and 3,050 warrants

Rhea-AI Filing Summary

ProMIS Neurosciences director Patrick D. Kirwin reported buying additional shares and warrants in the company. On February 3, 2026, he acquired 3,050 common shares and warrants to purchase 3,050 common shares under a Securities Purchase Agreement at $12.13 per share and warrant.

Following the transaction, he directly holds 5,135 common shares and warrants for 3,050 common shares with a $14.4 exercise price. He also indirectly beneficially owns 1,653 common shares through Patrick D. Kirwin Professional Corp and 305 common shares through his spouse. The filing notes a one-for-twenty-five reverse split completed on November 28, 2025, and states the warrants expire on the earlier of February 3, 2031 or within 60 days after topline PMN310 single ascending dose data is publicly announced.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Kirwin Patrick D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Warrants to purchase Common Shares	3,050	$0.00	--
Grant/Award	Common Shares	3,050	$12.13	$37K
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Warrants to purchase Common Shares — 3,050 shares (Direct); Common Shares — 5,135 shares (Direct); Common Shares — 1,653 shares (Indirect, By Patrick D. Kirwin Professional Corp)

Footnotes (1)

1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirwin Patrick D.

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

1920 YONGE STREET, SUITE 200

(Street)

TORONTO A6 M4S 3E2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/03/2026		A(1)		3,050	A	$12.13(1)	5,135(2)	D
Common Shares								1,653(2)	I	By Patrick D. Kirwin Professional Corp
Common Shares								305(2)	I	By his spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to purchase Common Shares	$14.4	02/03/2026		A(1)		3,050		02/03/2026	02/03/2031(3)	Common Shares	3,050	(1)	3,050	D

Explanation of Responses:

1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

2. Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

3. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

	/s/ Max A. Milbury, Attorney in Fact for Patrick Kirwin	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Patrick D. Kirwin report for ProMIS Neurosciences (PMN)?

Patrick D. Kirwin reported acquiring 3,050 ProMIS Neurosciences common shares and warrants for 3,050 common shares. The acquisition occurred on February 3, 2026 under a Securities Purchase Agreement with selected investors, as disclosed in his Form 4 filing.

At what price did Patrick D. Kirwin acquire ProMIS Neurosciences (PMN) shares and warrants?

He acquired the common shares and related warrants at $12.13 per common share and per common share warrant. This single purchase price applied to both the equity and the accompanying warrants in the February 3, 2026 transaction.

How many ProMIS Neurosciences (PMN) shares does Patrick D. Kirwin own after this transaction?

After the transaction, he directly owns 5,135 ProMIS common shares. In addition, he indirectly beneficially owns 1,653 common shares through Patrick D. Kirwin Professional Corp and 305 common shares through his spouse, according to the reported holdings.

What are the key terms of Patrick D. Kirwin’s ProMIS Neurosciences (PMN) warrants?

He holds warrants to purchase 3,050 ProMIS common shares at an exercise price of $14.4 per share. The warrants expire on February 3, 2031, or within 60 days after public topline PMN310 single ascending dose data is announced, whichever comes first.

What corporate action affecting ProMIS Neurosciences (PMN) shares is referenced in the Form 4?

The filing notes a one-for-twenty-five reverse split of ProMIS common shares. This reverse split was effected on November 28, 2025 and provides context for the share amounts shown in the reported holdings.

What is Patrick D. Kirwin’s relationship to ProMIS Neurosciences (PMN)?

Patrick D. Kirwin is reported as a director of ProMIS Neurosciences Inc. The Form 4 indicates he is not listed as an officer or a ten percent owner, and the filing is made for one reporting person.